Evolution of Hypolipidemic Drug Consumption in France From 2012 to 2022: Impact of European Society of Cardiology Guidelines

After the 2019 ESC guidelines for the management of dyslipidaemias, an increase in hypolipidemic drug sales in France was found, notably atorvastatin and ezetimibe. Healthcare costs have risen, particularly due to the increased sales of ezetimibe, which is a more expensive third-line treatment. Practice studies are needed to understand the determinants of this massive increase in ezetimibe sales.